GEA
GMAB icon

Glen Eagle Advisors’s Genmab GMAB Stock Holding History

Glen Eagle Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.49K Hold
200
– – ﹤0.01% 780
2026
Q1 		$5.37K Hold
200
– – ﹤0.01% 746
2025
Q4 		$6.16K Buy
+200
New +$6.23K ﹤0.01% 752
2021
Q2 		– Sell
-50
Closed -$1.64K – 1052
2021
Q1 		$1.64K Hold
50
– – ﹤0.01% 901
2020
Q4 		$2.03K Buy
+50
New +$1.87K ﹤0.01% 851

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Glen Eagle Advisors's GMAB Position: Q2 2026 in Review

Glen Eagle Advisors held its Genmab (GMAB) position steady in Q2 2026 at 200 shares worth $5.49K. The position accounts for ﹤0.01% of the portfolio, ranked #780.

Glen Eagle Advisors first reported a position in GMAB in Q4 2020 and has held it in 5 quarters since. The position peaked at $6.16K in Q4 2025. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Glen Eagle Advisors held 200 shares of Genmab worth $5.49K as of Q2 2026.
  • Glen Eagle Advisors left its Genmab share count unchanged in Q2 2026.
  • Genmab made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #780 holding.
  • Glen Eagle Advisors first reported a position in Genmab in Q4 2020 and has held it in 5 quarters since.
  • Glen Eagle Advisors's Genmab position peaked at $6.16K in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.